TABLE 3

The Incidence of Nonvaccine HPV Type–Related Persistent Infection, CIN, or EGLs Among Girls and Boys in the FAS Population

EVG Girls (FAS) N = 614CVG Girls (FAS) N = 262
No. of CasesRate per 100 Person-years95% CINo. of CasesRate per 100 Person-years95% CI
HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 related persistent infection909.8(7.4–11.3)6114.5(11.1–18.6)
CIN (any grade)171.6(0.9–2.6)132.4(1.3–4.1)
 CIN 1171.6(0.9–2.6)132.4(1.3–4.1)
 CIN 220.2(0.0–0.7)20.4(0.0–1.3)
 CIN 310.1(0.0–0.5)00.0(0.0–0.7)
EGL20.2(0.0–0.6)10.2(0.0–0.9)
 Condyloma (vulvar or vaginal)10.1(0.0–0.4)00.0(0.0–0.6)
 VIN 1 or VaIN 110.1(0.0–0.4)10.2(0.0–0.9)
 VIN 2/3 or VaIN 2/3 or worse00.0(0.0–0.3)00.0(0.0–0.6)
EVG Boys (FAS) N = 565CVG Boys (FAS) N = 220
No. of CasesRate per 100 Person-years95% CINo. of CasesRate per 100 Person-years95% CI
HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 related persistent infection344.8(3.3–6.7)195.3(3.1–8.1)
EGL00.0(0.0–0.5)00.0(0.0–0.9)
  • CIN, cervical intraepithelial neoplasia; EGL, external genital lesion; FAS, full analysis set; N, number of subjects in the indicated group who received at least 1 dose of the 4vHPV vaccine; VaIN, vaginal intraepithelial neoplasia; VIN, vulvar intraepithelial neoplasia.